CA2423568A1 — Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
Assigned to Kissei Pharmaceutical Co Ltd · Expires 2002-04-11 · 24y expired
What this patent protects
Glucopyranosyloxybenzylbenzene derivatives represented by the following general formula (I) which have an improved oral absorbability, exert an excellent effect of inhibiting human SGLT2 activity in vivo and, therefore, are useful as preventives or remedies for diseases caused by…
USPTO Abstract
Glucopyranosyloxybenzylbenzene derivatives represented by the following general formula (I) which have an improved oral absorbability, exert an excellent effect of inhibiting human SGLT2 activity in vivo and, therefore, are useful as preventives or remedies for diseases caused by hyperglycemia such as diabetes, complication of diabetes and obesity wherein P represents a group constituting a prodrug; and R represents lower alkyl, lower alkoxy, lower alkylthio, lower alkoxy lower alkyl, lower alkoxy lower alkoxy or lowe r alkoxy lower alkylthio.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.